Search

Gambia-Swansea Partnership: Technical support in our 16-year partnership

I have been involved in the Gambia-Swansea VISION 2020 LINK now for more than 16 years. I hope that this article will be of some interest to anyone considering volunteering overseas, as part of a LINK or in any other...

Act now: Professor Serge Resnikoff on making myopia a public health priority

Over the past decade, myopia has shifted from a common childhood inconvenience to what global health leaders now call a “public health emergency in slow motion” [1]. According to Professor Serge Resnikoff, former Head of Eye Health at the World...

The role of artificial intelligence in cataract surgery: An overview

Cataracts are still a leading cause of blindness and, with an ageing population, that burden will only grow [1]. Increasingly experts are leaning on technology such as ‘Surgery 4.0’ [2] – where smart machines and artificial intelligence (AI) slide into...

Ocular surface special: Ocular manifestations of Stevens-Johnson syndrome

Stevens–Johnson syndrome (SJS) is an uncommon dermatological emergency on the same clinical spectrum as toxic epidermal necrolysis (TEN). SJS is characterised by an acute, immune-mediated attack on the skin and mucous membranes, producing a rapidly progressive erythematous eruption with blistering...

Ciclosporin and dry eye

Dry eye has an estimated prevalence of between 5 and 50% worldwide and has physical, psychological and socioeconomic consequences for the human population [1]. Loss of tear film homeostasis with associated ocular surface inflammation causes symptoms ranging from ‘tired’ eyes...

South-South collaboration for the treatment of avoidable blindness in Botswana

This article describes the value of South-South collaboration in the reduction of avoidable blindness. Specifically it describes a South-South collaboration between India and Botswana that evolved out of the VISION 2020 LINK between Cambridge University Hospitals, two institutions in India...

A look into the IOL space

Advances in the design and performance of intraocular lenses (IOLs) continue to be driven by demand for better outcomes, presbyopia correction and spectacle independence, alongside a better understanding of the dynamics of the crystalline lens, newer theories of accommodation and...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...